Xia M Q, Qin S X, Wu L J, Mackay C R, Hyman B T
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown 02129, USA.
Am J Pathol. 1998 Jul;153(1):31-7. doi: 10.1016/s0002-9440(10)65542-3.
Chemokines belong to an expanding family of cytokines the primary function of which is recruitment of leukocytes to inflammatory sites. Recent evidence has shown their presence in the central nervous system. Because inflammatory responses have been implicated in the pathogenesis of Alzheimer's disease (AD), we studied the expression of CCR3, CCR5, and their ligands in normal and AD brains by immunohistochemistry. CCR3 and CCR5 are present on microglia of both control and AD brains, with increased expression on some reactive microglia in AD. Immunohistochemistry for MIP-1beta, MIP-1alpha, RANTES, eotaxin, and MCP-3 (ligands for CCR5 and/or CCR3) revealed the presence of MIP-1beta predominantly in a subpopulation of reactive astrocytes, which were more widespread in AD than control brains, and MIP-1alpha predominantly in neurons and weakly in some microglia in both AD and controls. Many of the CCR3+ or CCR5+ reactive microglia and MIP-1beta+ reactive astrocytes were found associated with amyloid deposits. Immunoreactivity for eotaxin, RANTES, and MCP-3 were not detected. Detection of these beta-chemokine receptors on microglia and some of their ligands in reactive astrocytes and neurons as well as microglia suggests a role for this system in glial-glial and glial-neuronal interactions, potentially influencing the progression of AD.
趋化因子属于不断扩展的细胞因子家族,其主要功能是将白细胞募集到炎症部位。最近的证据表明它们存在于中枢神经系统中。由于炎症反应与阿尔茨海默病(AD)的发病机制有关,我们通过免疫组织化学研究了正常脑和AD脑中CCR3、CCR5及其配体的表达。CCR3和CCR5存在于对照脑和AD脑的小胶质细胞上,在AD的一些反应性小胶质细胞上表达增加。对MIP-1β、MIP-1α、RANTES、嗜酸性粒细胞趋化因子和MCP-3(CCR5和/或CCR3的配体)进行免疫组织化学分析发现,MIP-1β主要存在于反应性星形胶质细胞亚群中,在AD脑中比对照脑更广泛,而MIP-1α主要存在于神经元中,在AD和对照的一些小胶质细胞中表达较弱。许多CCR3+或CCR5+反应性小胶质细胞和MIP-1β+反应性星形胶质细胞与淀粉样沉积物相关。未检测到嗜酸性粒细胞趋化因子、RANTES和MCP-3的免疫反应性。在小胶质细胞上检测到这些β趋化因子受体以及反应性星形胶质细胞和神经元以及小胶质细胞中的一些配体,表明该系统在胶质-胶质和胶质-神经元相互作用中发挥作用,可能影响AD的进展。